Previous 10 | Next 10 |
home / stock / lbtsf / lbtsf news
Almirall's 2020 Full-Year Results Almirall delivers on latest 2020 guidance and sets growth targets for 2021 PR Newswire BARCELONA, Spain , Feb. 22, 2021 /PRNewswire/ -- The company delivered on its latest guidance despite a challenging year impacted ...
Almirall and MC2 Therapeutics enter a license, collaboration and commercialization agreement for European rights to Wynzora® Cream for treatment of plaque psoriasis -- In this collaboration Almirall will commercialize Wynzora® Cream for treatment of plaque psoriasis in...
Almirall announces Gianfranco Nazzi as new CEO Gianfranco Nazzi brings broad international experience from a distinguished career in Pharma Mr. Nazzi will join Almirall as Chief Executive Officer on May 1, 2021 PR Newswire BARCELONA, Spain , Feb. 3, 2021 ...
Almirall and Happify Health enter into strategic partnership to develop evidence-supported digital therapeutics solutions for psoriasis patients -- The goal of this strategic partnership is to develop digital solutions to improve the lives of patients with psoriasis based on cog...
Almirall and Tyris Therapeutics enter into strategic partnership to develop next generation gene therapies - The goal of this strategic partnership is to develop ground-breaking drugs for the treatment of debilitating genetic dermatological conditions - Tyris' expertise in n...
Athenex (ATNX) jumps 10% premarket on after FDA approved Klisyri (tirbanibulin) for the topical treatment of actinic keratosis ((AK)) on the face or scalp.Klisyri is the first FDA approved branded proprietary product for Athenex and will be launched in partnership with Almirall (LBT...
Almirall announces collaborations with the University of South Australia and Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau PR Newswire BARCELONA, Spain, Nov. 24, 2020 BARCELONA, Spain , Nov. 24, 2020 /PRNewswire/ -- AlmirallSha...
Pablo Alvarez appointed to President and GM of Almirall US - Pablo will report directly to the CEO and serve on the Management Board effective immediately - He brings to this important role broad international pharmaceutical industry experience, including nearly 10 years in ...
The following slide deck was published by Almirall, S.A. in conjunction with their 2020 Q3 earnings call. For further details see: Almirall, S.A. 2020 Q3 - Results - Earnings Call Presentation
Almirall SA (LBTSF) Q3 2020 Results Conference Call November 09, 2020 04:00 AM ET Company Participants Pablo Divasson del Fraile - Head of Investor Relations Peter Guenter - Chief Executive Officer Michael McClellan - Chief Financial Officer Conference Call Participants Trung Huynh - Credit S...
News, Short Squeeze, Breakout and More Instantly...
Almirall Sa Ord Company Name:
LBTSF Stock Symbol:
OTCMKTS Market:
Almirall’s sustainability strategy focuses on five pillars: Planet, People, Patients, Partners and Principles defining clear targets and measurements Among other commitments, Almirall aims to – by 2030 - reduce absolute direct greenhouse gas emissions by 50%, minimize the ge...
Almirall presented the interim Week 52 results of the POSITIVE clinical study at the IFPA Conference 2024, showing the benefits of the effective treatment with Ilumetri (tildrakizumab) in patients with moderate to severe psoriasis achieving improvement of physical symptoms and overall wellbeing. ...
Positive trajectory with Net Sales increase by 6.6% to a total of €247.4 MM, EBITDA increase of 1.4% YoY to a total of €52.5 MM driven by higher overall sales Performance driven by biologics as key growth engines, with Ilumetri ® showing 30% increase in sales vs Q1 ...